Clinical efficacy of montelukast sodium combined with budesonide or combined with loratadine in treating children with cough variant asthma and influence on inflammatory factors in the serum

Wei,Haiyan; Li,Weihua; Jiang,Zhen; Xi,Xiaoying; Qi,Gongjian

doi:10.3892/etm.2019.7574

Clinical efficacy of montelukast sodium combined with budesonide or combined with loratadine in treating children with cough variant asthma and influence on inflammatory factors in the serum

Authors:
- Haiyan Wei
- Weihua Li
- Zhen Jiang
- Xiaoying Xi
- Gongjian Qi
View Affiliations

Affiliations: Department of Intensive Care Unit, Xuzhou Children's Hospital, Xuzhou Medical University, Xuzhou, Jiangsu 221006, P.R. China
Published online on: May 10, 2019 https://doi.org/10.3892/etm.2019.7574
Pages: 411-417

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Clinical efficacy of montelukast sodium combined with budesonide or combined with loratadine in children with cough variant asthma was investigated. A retrospective analysis of the medical records of 72 children with cough variant asthma who were treated in Xuzhou Children's Hospital, Xuzhou Medical University from April 2015 to August 2017 was performed and the 72 child patients were divided into two groups: 35 children were treated with montelukast sodium combined with budesonide in Group A, and 37 children were treated with montelukast sodium combined with loratadine in Group B. The clinical efficacy of the two groups was evaluated according to the lung function indexes [forced expiratory volume in the first second (FEV1), ratio of the forced expiratory volume in the first second to the forced vital capacity (FEV1/FVC), the peak expiratory flow (PEF)], the inflammation biomarkers [tumor necrosis factor‑α (TNF‑α) and interleukin‑4 (IL‑4)], the level of eosinophil granulocyte, and the level of IgE at three time‑points: before treatment, the 4th week after treatment, and the 12th week after treatment as well as adverse reactions, recurrence of symptoms, and treatment compliance were recorded. After treatment, the levels of FEV1, FEV1/FVC, PEF, TNF‑α and IL‑4, eosinophil granulocyte and IgE in the two groups were significantly improved (P<0.05). The treatment compliance of Group A was significantly lower than that of Group B (P<0.05). In conclusion, the method of montelukast sodium combined with budesonide or loratadine are both worthy of clinical promotion because they have equivalent efficacy in the treatment of cough variant asthma to effectively improve the lung function and inflammatory response in patients and both bring less adverse reactions and lower recurrence rate.

View Figures

View References

1	Hossain SS, Islam MS, Rahman MM, Dey S and Mahmud K: Clinical and demographic profiles of patients diagnosed as cough variant asthma attended at Tertiary Referral Hospital. JNINB. 2:12016.
2	Kanemitsu Y, Niimi A, Matsumoto H, Iwata T, Ito I, Oguma T, Inoue H, Tajiri T, Nagasaki T, Izuhara Y, et al: Gastroesophageal dysmotility is associated with the impairment of cough-specific quality of life in patients with cough variant asthma. Allergol Int. 65:320–326. 2016. View Article : Google Scholar : PubMed/NCBI
3	Tagaya E, Kondo M, Kirishi S, Kawagoe M, Kubota N and Tamaoki J: Effects of regular treatment with combination of salmeterol/fluticasone propionate and salmeterol alone in cough variant asthma. J Asthma. 52:512–518. 2015. View Article : Google Scholar : PubMed/NCBI
4	Tajiri T, Niimi A, Matsumoto H, Ito I, Oguma T, Otsuka K, Takeda T, Nakaji H, Inoue H, Iwata T, et al: Prevalence and clinical relevance of allergic rhinitis in patients with classic asthma and cough variant asthma. Respiration. 87:211–218. 2014. View Article : Google Scholar : PubMed/NCBI
5	Evans DJ, Taylor DA, Zetterstrom O, Chung KF, O'Connor BJ and Barnes PJ: A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. N Engl J Med. 337:1412–1418. 1997. View Article : Google Scholar : PubMed/NCBI
6	Bao W, Chen Q, Lin Y, Liu H, Zhao G, Chen Z and Zhou X: Efficacy of procaterol combined with inhaled budesonide for treatment of cough-variant asthma. Respirology. 18 (Suppl 3):53–61. 2013. View Article : Google Scholar : PubMed/NCBI
7	Frølund L: Efficacy of an oral antihistamine, loratadine, as compared with a nasal steroid spray, beclomethasone dipropionate, in seasonal allergic rhinitis. Clin Otolaryngol Allied Sci. 16:527–531. 1991. View Article : Google Scholar : PubMed/NCBI
8	Wang X, Liu B, Lu B, Zhang Y, Wang L, Li H, Han X and Ding D: Micro-invasive embedding combined with montelukast sodium for children cough variant asthma: A randomized controlled trial. Zhongguo Zhen Jiu. 37:259–264. 2017.(In Chinese). PubMed/NCBI
9	Zhou X, Hong J, Cheng H, Xie J, Yang J, Chen Q, He S, Li Y, Zhou X and Li C: Budesonide suspension nebulization treatment in Chinese pediatric patients with cough variant asthma: A multi-center observational study. J Asthma. 53:532–537. 2016. View Article : Google Scholar : PubMed/NCBI
10	Steffey EP, Mama KR, Galey FD, Puschner B and Woliner MJ: Effects of sevoflurane dose and mode of ventilation on cardiopulmonary function and blood biochemical variables in horses. Am J Vet Res. 66:606–614. 2005. View Article : Google Scholar : PubMed/NCBI
11	Wei Y, Li DS, Liu JJ, Zhang J and Zhao HE: Therapeutic effect and safety of montelukast sodium combined with budesonide in children with cough variant asthma: A meta analysis. Zhongguo Dang Dai Er Ke Za Zhi. 18:1100–1105. 2016.(In Chinese). PubMed/NCBI
12	Wang XP, Yang LD and Zhou JF: Montelukast and budesonide combination for children with chronic cough-variant asthma. Medicine (Baltimore). 97:e115572018. View Article : Google Scholar : PubMed/NCBI
13	Xiao Q and Qin X: Effects of salmeterol xinafoate and fluticasone propionate powder in combination with montelukast on pulmonary function and serum inflammatory cytokines in children with cough variant asthma. Zhongguo Jiceng Yiyao. 25:182–185. 2018.(In Chinese).
14	Jiao HY, Su WW, Li PB, Liao Y, Zhou Q, Zhu N and He LL: Therapeutic effects of naringin in a guinea pig model of ovalbumin-induced cough-variant asthma. Pulm Pharmacol Ther. 33:59–65. 2015. View Article : Google Scholar : PubMed/NCBI
15	Takemura M, Niimi A, Matsumoto H, Ueda T, Yamaguchi M, Matsuoka H, Jinnai M, Chin K and Mishima M: Atopic features of cough variant asthma and classic asthma with wheezing. Clin Exp Allergy. 37:1833–1839. 2007. View Article : Google Scholar : PubMed/NCBI
16	Saito N, Itoga M, Tamaki M, Yamamoto A and Kayaba H: Cough variant asthma patients are more depressed and anxious than classic asthma patients. J Psychosom Res. 79:18–26. 2015. View Article : Google Scholar : PubMed/NCBI
17	Dicpinigaitis PV: Chronic cough due to asthma: ACCP evidence-based clinical practice guidelines. Chest. 129 (Suppl 1):75S–79S. 2006. View Article : Google Scholar : PubMed/NCBI
18	Usta Guc B, Asilsoy S and Durmaz C: The assessment and management of chronic cough in children according to the British Thoracic Society guidelines: Descriptive, prospective, clinical trial. Clin Respir J. 8:330–337. 2014. View Article : Google Scholar : PubMed/NCBI
19	Matsuse H and Kohno S: Leukotriene receptor antagonists pranlukast and montelukast for treating asthma. Expert Opin Pharmacother. 15:353–363. 2014. View Article : Google Scholar : PubMed/NCBI
20	Sun LH, Chen AH and Zhang Y: Therapeutic efficacy and follow-up study of inhaled corticosteroids vs. oral montelukast in treatment of cough variant asthma. Zhonghua Er Ke Za Zhi. 46:85–88. 2008.(In Chinese). PubMed/NCBI
21	Peng QF and Kong LF: The levels of nerve growth factor and IL-4 in induced sputum and characteristics of airway inflammation in cough variant asthma. Zhonghua Nei Ke Za Zhi. 50:221–224. 2011.(In Chinese). PubMed/NCBI
22	Fujimura M, Ogawa H, Nishizawa Y and Nishi K: Comparison of atopic cough with cough variant asthma: Is atopic cough a precursor of asthma? Thorax. 58:14–18. 2003. View Article : Google Scholar : PubMed/NCBI
23	Sanchis J, Gich I and Pedersen S; Aerosol Drug Management Improvement Team (ADMIT), : Systematic review of errors in inhaler use: Has patient technique improved over time? Chest. 150:394–406. 2016. View Article : Google Scholar : PubMed/NCBI
24	Deuse T, Hua X, Stubbendorff M, Spin JM, Neofytou E, Taylor V, Chen Y, Park G, Fink JB, Renne T, et al: The selective JAK1/3-inhibitor R507 mitigates obliterative airway disease both with systemic administration and aerosol inhalation. Transplantation. 100:1022–1031. 2016. View Article : Google Scholar : PubMed/NCBI